{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T16:54:17Z","timestamp":1769273657924,"version":"3.49.0"},"reference-count":169,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2024,5,23]]},"DOI":"10.1080\/14656566.2024.2365326","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T07:53:37Z","timestamp":1718006017000},"page":"999-1017","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacotherapeutic advances in fibromyalgia: what\u2019s new on the horizon?"],"prefix":"10.1080","volume":"25","author":[{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"first","affiliation":[{"name":"IRCCS Ospedale Galeazzi Sant\u2019Ambrogio","place":["Milan, Italy"]},{"name":"University of Milan","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Giorgi","sequence":"additional","affiliation":[{"name":"Gruppo Ospedaliero Moncucco","place":["Lugano, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Sirotti","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Galeazzi Sant\u2019Ambrogio","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bazzichi","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Galeazzi Sant\u2019Ambrogio","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Lucini","sequence":"additional","affiliation":[{"name":"University of Milan","place":["Milan, Italy"]},{"name":"Exercise Medicine Unit","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Di Lascio","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greta","family":"Pellegrino","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Galeazzi Sant\u2019Ambrogio","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Fornasari","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00506-w"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3266"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.08.012"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2018.10.008"},{"key":"e_1_3_4_7_1","first-page":"90","article-title":"Fibromyalgia syndrome: under-, over- and misdiagnosis","volume":"37","author":"H\u00e4user W","year":"2019","unstructured":"H\u00e4user W, Sarzi-Puttini P, Fitzcharles MA. Fibromyalgia syndrome: under-, over- and misdiagnosis. Clin Exp Rheumatol. 2019;37:90\u201397.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_8_1","first-page":"555","article-title":"Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population","volume":"24","author":"Wolfe F","year":"1997","unstructured":"Wolfe F, Russell IJ, Vipraio G, et al. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol. 1997 [cited 2019 Oct 14];24:555\u2013559. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9058665","journal-title":"J Rheumatol"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.SEMARTHRIT.2014.01.001"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS241310443"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13392"},{"issue":"3","key":"e_1_3_4_12_1","first-page":"198","article-title":"Clinical Endocannabinoid Deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?","volume":"35","author":"Smith SC","year":"2014","unstructured":"Smith SC, Wagner MS. Clinical Endocannabinoid Deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2014;35(3):198\u2013201. NEL290208R02 [pii].","journal-title":"Neuro Endocrinol Lett"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES5020015"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00353"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000002130"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20205164"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/J.PAIN.0000000000001815"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBI.2018.09.018"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1101\/2022.07.06.498940%0Ahttps:\/\/www.biorxiv.org\/content\/10.1101\/2022.07.06.498940v1%0Ahttps:\/\/www.biorxiv.org\/content\/10.1101\/2022.07.06.498940v1.abstract"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035677"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12550"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3182a225dd"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(00)80008-6"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.3344\/KJP.2022.35.3.327"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-27581-9"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01810-6"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2023.109685"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22970"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/i19pig"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/AR4441\/TABLES\/3"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/11598970-000000000-00000"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2022.12939"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.20452\/PAMW.16432"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/S10067-022-06129-8"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20485"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.41.2.104"},{"key":"e_1_3_4_37_1","unstructured":"Study Details | Comparative Efficacy of Duloxetine vs Escitalopram in Patients with Fibromyalgia | ClinicalTrials.Gov. n.d [cited 2023 Dec 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03487211?cond=Fibromyalgia%20%5C(FM%5C)&start=2016-06-01_2023-12-04&aggFilters=phase:3&rank=9"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLINTHERA.2008.11.009"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.PSYM.2012.02.005"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S162810"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ART.20983"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40199-019-00257-4"},{"key":"e_1_3_4_43_1","unstructured":"Parliamentary question | Answer to Question No E-003801\/18 | E-003801\/2018(ASW). |. European Parliament; n.d [cited 2024 May 6]. Available from: https:\/\/www.europarl.europa.eu\/doceo\/document\/E-8-2018-003801-ASW_EN.html"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2016-0012"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000079"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/EJP.2136"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/J.PAIN.0000000000002878"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443130-00004\/METRICS"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(03)00116-5"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/IJCP.13455"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S402362"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13085-5"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1435"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40122-014-0023-5\/FIGURES\/4"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ-2022-072415"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.DDTEC.2015.06.003"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1046\/J.1365-2125.2003.01723.X"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.579944"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/S11739-022-03054-1"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.2478\/JOMB-2019-0033"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1582432"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20076"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110194"},{"key":"e_1_3_4_65_1","unstructured":"Study Details | A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia | ClinicalTrials.gov. n.d [cited 2023 Dec 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04172831?cond=Fibromyalgia%20%5C(FM%5C)&start=2016-06-01_2023-12-04&aggFilters=phase:3&rank=2"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/ACR.25142"},{"key":"e_1_3_4_67_1","unstructured":"Study Details | A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia | ClinicalTrials.gov. n.d [cited 2023 Dec 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04508621?cond=Fibromyalgia%20%5C(FM%5C)&start=2016-06-01_2023-12-04&aggFilters=phase:3&rank=4"},{"key":"e_1_3_4_68_1","unstructured":"Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia : Tonix Pharmaceuticals Holding Corp. (TNXP). n.d [cited 2023 Dec 5]. Available from: https:\/\/ir.tonixpharma.com\/news-events\/press-releases\/detail\/1271\/tonix-pharmaceuticals-announces-outcome-of-interim-analysis"},{"key":"e_1_3_4_69_1","unstructured":"Study Details | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia (RESILIENT). ClinicalTrials.gov. n.d [cited 2023 Dec 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05273749?cond=Fibromyalgia%20%5C(FM%5C)&start=2016-06-01_2023-12-04&aggFilters=phase:3&rank=3"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(97)82001-3"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00002.2016"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40122-022-00434-5"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011694.pub2"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124448"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2022.113552"},{"key":"e_1_3_4_76_1","article-title":"Genome-wide expression profiling in the peripheral blood of patients with fibromyalgia","volume":"34","author":"Jones KD","year":"2016","unstructured":"Jones KD, Gelbart T, Whisenant TC, et al. Genome-wide expression profiling in the peripheral blood of patients with fibromyalgia. Clin Exp Rheumatol. 2016 [cited 2023 Nov 23];34. Available from: 89.\/pmc\/articles\/PMC4888802\/","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33338"},{"key":"e_1_3_4_78_1","first-page":"192","article-title":"Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?","volume":"29","author":"Russo EB","year":"2008","unstructured":"Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuro Endocrinol Lett. 2008 [cited 2019 Mar 29];29:192\u2013200. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18404144","journal-title":"Neuro Endocrinol Lett"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108216"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1561"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707458"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.2147\/itt.s267905"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.MTBIO.2023.100808"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/J.1476-5381.2011.01589.X"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)00798-1"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.5056\/JNM.2010.16.3.281"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/827290"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnaa303"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060807"},{"key":"e_1_3_4_90_1","first-page":"53","article-title":"Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study","volume":"38","author":"Giorgi V","year":"2020","unstructured":"Giorgi V, Bongiovanni S, Atzeni F, et al. Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. Clin Exp Rheumatol. 2020;38:53\u201359.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_91_1","unstructured":"Yassin M Oron A Robinson D. Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study. Clin Exp Rheumatol 37 Suppl11. 2019 [cited 2019 Mar 29]. p. 13\u201320. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30418116"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/ACR.24985"},{"key":"e_1_3_4_93_1","unstructured":"Study Details | CBD (Cannabidiol)\/THC (Tetrahydrocannabinol) Solution as a Pharmacological Strategy for Patients With Fibromyalgia (FibroCann) | ClinicalTrials.gov. n.d [cited 2023 Dec 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05283161?cond=Fibromyalgia%20%5C(FM%5C)&start=2016-06-01_2023-12-04&aggFilters=phase:3&rank=7"},{"key":"e_1_3_4_94_1","unstructured":"Study Details | Phase II Clinical Trial Use of KL16-012 in Women With Fibromyalgia Refractary to Conventional Treatment. | ClinicalTrials.gov. n.d [cited 2023 Dec 12]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04239469?cond=Fibromyalgia%20%5C(FM%5C)&start=2016-06-01_2023-12-04&aggFilters=phase:2&page=3&rank=24"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2020.12.001"},{"key":"e_1_3_4_96_1","unstructured":"Study Details | Cannabidiol for Fibromyalgia (The CANNFIB Trial) | ClinicalTrials.gov. n.d [cited 2023 Nov 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04729179?cond=Fibromyalgia%20%5C(FM%5C)&aggFilters=phase:2%203%204 studyType:obs%20int&page=6&rank=56"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1089\/can.2018.0073"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2016.00007"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26913"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz017"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ-2022-072348"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.0509494102"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049909119838974"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/J.1526-4637.2009.00613.X"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37734"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES5020016"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1093\/PM\/PNAA001"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.3389\/FPSYT.2021.593842"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES11041087"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.BJANE.2022.08.003"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22677"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN-2021-055351"},{"key":"e_1_3_4_113_1","unstructured":"Study Details | Fibromyalgia and Naltrexone: The FINAL Study | ClinicalTrials.gov. n.d [cited 2023 Nov 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04270877?cond=Fibromyalgia%20%5C(FM%5C)&aggFilters=phase:2%203%204 studyType:obs%20int&intr=Naltrexone&rank=2"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-020-00898-0"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1093\/IJNP\/PYX096"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1124\/PR.117.015198"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(99)00308-5"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPAIN.2011.03.008"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.31486\/TOJ.21.0038"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.4172\/foa.1000104"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.14740\/jmc.v9i5.3017"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S110261"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1186\/S13063-021-05814-4\/FIGURES\/3"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2023.14406"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/NM0498-460"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JNS.2020.116778"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1124\/JPET.118.249409"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.MEDIDD.2020.100067"},{"key":"e_1_3_4_129_1","unstructured":"Results Posted | Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia | ClinicalTrials.gov. n.d [cited 2023 Nov 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04147858?cond=Fibromyalgia%20%5C(FM%5C)&aggFilters=phase:2%203%204 studyType:obs%20int&page=7&rank=63&tab=results"},{"key":"e_1_3_4_130_1","unstructured":"Study Results | Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia | ClinicalTrials.gov. n.d [cited 2023 Nov 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03249103?cond=Fibromyalgia%20%5C(FM%5C)&aggFilters=phase:2%203%204 studyType:obs%20int&page=6&rank=55&tab=results"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119479"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2021.105874"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S190231"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200203040-00001"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12493"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0476-2"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2014.02.005"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2007.06.013"},{"key":"e_1_3_4_139_1","first-page":"S82","article-title":"A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data","volume":"33","author":"Leombruni P","year":"2015","unstructured":"Leombruni P, Miniotti M, Colonna F, et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clin Exp Rheumatol. 2015;33:S82\u2013S85.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1111\/BCP.13020"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1111\/BPH.13580"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.36076\/ppj\/2016.19.11"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871527318666190227205359"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40122-015-0038-6\/TABLES\/2"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.55563\/CLINEXPRHEUMATOL\/PMDZCQ"},{"key":"e_1_3_4_146_1","unstructured":"Study Details | A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia | ClinicalTrials.gov. n.d [cited 2023 Dec 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03965091?cond=Fibromyalgia%20%5C(FM%5C)&aggFilters=phase:2%203%204 studyType:obs%20int&page=9&rank=81"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.46497\/ARCHRHEUMATOL.2020.7783"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS242115533"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.AAN1208\/SUPPL_FILE\/AAN1208_SM.PDF"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7"},{"key":"e_1_3_4_151_1","unstructured":"Study Details | A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome | ClinicalTrials.gov. n.d [cited 2023 Dec 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05643794?cond=Fibromyalgia%20%5C(FM%5C)&aggFilters=phase:2%203%204 studyType:obs%20int&page=3&rank=27"},{"key":"e_1_3_4_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JPHS.2023.02.003"},{"key":"e_1_3_4_153_1","unstructured":"Results Posted | A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia | ClinicalTrials.gov. n.d [cited 2023 Dec 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03056690?cond=Fibromyalgia%20%5C(FM%5C)&aggFilters=phase:2%203%204 studyType:obs%20int&page=7&rank=66&tab=results"},{"key":"e_1_3_4_154_1","unstructured":"Results Posted | A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia | ClinicalTrials.gov. n.d [cited 2023 Dec 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03092726?cond=Fibromyalgia%20%5C(FM%5C)&aggFilters=phase:2%203%204 studyType:obs%20int&page=6&rank=60&tab=results"},{"key":"e_1_3_4_155_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S274562"},{"key":"e_1_3_4_156_1","unstructured":"Study Details | The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia | ClinicalTrials.gov. n.d [cited 2023 Dec 12]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04594733?cond=Fibromyalgia%20%5C(FM%5C)&aggFilters=phase:2%203%204 studyType:obs%20int&page=7&rank=67"},{"key":"e_1_3_4_157_1","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X17718106"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0012490"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.28.437090"},{"key":"e_1_3_4_160_1","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.336136"},{"key":"e_1_3_4_161_1","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0282406"},{"key":"e_1_3_4_162_1","doi-asserted-by":"publisher","DOI":"10.2169\/INTERNALMEDICINE.6082-20"},{"key":"e_1_3_4_163_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03018952\/METRICS"},{"key":"e_1_3_4_164_1","doi-asserted-by":"publisher","DOI":"10.1111\/FCP.12076"},{"key":"e_1_3_4_165_1","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0254642"},{"key":"e_1_3_4_166_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209724"},{"key":"e_1_3_4_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.BJA.2019.07.026"},{"key":"e_1_3_4_168_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6266619"},{"key":"e_1_3_4_169_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1121"},{"key":"e_1_3_4_170_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221897"},{"key":"e_1_3_4_171_1","first-page":"S39","article-title":"Potentially traumatic events, post-traumatic stress disorder and post-traumatic stress spectrum in patients with fibromyalgia","volume":"37","author":"Conversano C","year":"2019","unstructured":"Conversano C, Carmassi C, Bertelloni CA, et al. Potentially traumatic events, post-traumatic stress disorder and post-traumatic stress spectrum in patients with fibromyalgia. Clin Exp Rheumatol. 2019;37:S39\u2013S43.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2024.2365326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T07:08:30Z","timestamp":1738220910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2024.2365326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":169,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,5,23]]}},"alternative-id":["10.1080\/14656566.2024.2365326"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2024.2365326","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-03-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}